Multivariable analysis for 7/8 HLA-MUD HCT vs haploidentical HCT, 2013-2017
| Covariate . | No. . | HR . | 95% Confidence interval . | P . |
|---|---|---|---|---|
| OS | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| 7/8 HLA-MUD HCT | 230 | 1.38 | 1.08-1.78 | .01 |
| Remission status | ||||
| CR1 | 418 | Reference | ||
| CR2+ | 205 | 1.82 | 1.41-2.34 | <.001 |
| LFS | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| 7/8 HLA-MUD | 227 | 1.21 | 0.95-1.54 | .12 |
| Remission status | ||||
| CR1 | 414 | Reference | ||
| CR2+ | 194 | 1.84 | 1.46-2.33 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 124 | Reference | ||
| White non-Hispanic | 277 | 0.95 | 0.71-1.28 | .73 |
| Black | 75 | 1.33 | 0.92-1.94 | .13 |
| Asian | 32 | 0.50 | 0.25-0.97 | .04 |
| Other/not specified | 100 | 0.70 | 0.48-1.03 | .07 |
| Conditioning regimen | ||||
| MAC-TBI | 295 | Reference | ||
| MAC-chemotherapy | 111 | 1.29 | 0.94-1.75 | .11 |
| RIC/NMA | 201 | 1.46 | 1.12-1.89 | .005 |
| NRM | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| 7/8 HLA-MUD HCT | 227 | 2.13 | 1.50-3.01 | <.001 |
| Donor/recipient CMV serostatus | ||||
| +/+ | 287 | Reference | ||
| +/− | 55 | 0.40 | 0.18-0.86 | .02 |
| −/+ | 143 | 0.78 | 0.51-1.19 | .25 |
| −/− | 121 | 0.56 | 0.34-0.92 | .02 |
| Relapse | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| 7/8 HLA-MUD HCT | 227 | 0.81 | 0.57-1.13 | .22 |
| Remission status | ||||
| CR1 | 414 | Reference | ||
| CR2+ | 194 | 2.39 | 1.76-3.25 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 124 | Reference | ||
| White non-Hispanic | 277 | 0.94 | 0.64-1.39 | .76 |
| Black | 75 | 1.24 | 0.76-2.02 | .38 |
| Asian | 32 | 0.36 | 0.14-0.93 | .03 |
| Other/not specified | 100 | 0.58 | 0.34-0.99 | .05 |
| Conditioning regimen | ||||
| MAC-TBI | 295 | Reference | ||
| MAC-chemotherapy | 111 | 1.60 | 1.05-2.44 | .03 |
| RIC/NMA | 201 | 2.09 | 1.49-2.95 | <.001 |
| aGVHD, grade 2-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| 7/8 HLA-MUD HCT | 216 | 1.33 | 1.02-1.73 | .04 |
| Conditioning regimen | ||||
| MAC-TBI | 288 | Reference | ||
| MAC-chemotherapy | 107 | 0.68 | 0.47-0.98 | .04 |
| RIC/NMA | 196 | 0.68 | 0.51-0.92 | .01 |
| aGVHD, grade 3-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| 7/8 HLA-MUD HCT | 216 | 1.86 | 1.23-2.80 | .003 |
| cGVHD | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| 7/8 HLA-MUD HCT | 230 | 1.72 | 1.34-2.20 | <.001 |
| Covariate . | No. . | HR . | 95% Confidence interval . | P . |
|---|---|---|---|---|
| OS | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| 7/8 HLA-MUD HCT | 230 | 1.38 | 1.08-1.78 | .01 |
| Remission status | ||||
| CR1 | 418 | Reference | ||
| CR2+ | 205 | 1.82 | 1.41-2.34 | <.001 |
| LFS | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| 7/8 HLA-MUD | 227 | 1.21 | 0.95-1.54 | .12 |
| Remission status | ||||
| CR1 | 414 | Reference | ||
| CR2+ | 194 | 1.84 | 1.46-2.33 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 124 | Reference | ||
| White non-Hispanic | 277 | 0.95 | 0.71-1.28 | .73 |
| Black | 75 | 1.33 | 0.92-1.94 | .13 |
| Asian | 32 | 0.50 | 0.25-0.97 | .04 |
| Other/not specified | 100 | 0.70 | 0.48-1.03 | .07 |
| Conditioning regimen | ||||
| MAC-TBI | 295 | Reference | ||
| MAC-chemotherapy | 111 | 1.29 | 0.94-1.75 | .11 |
| RIC/NMA | 201 | 1.46 | 1.12-1.89 | .005 |
| NRM | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| 7/8 HLA-MUD HCT | 227 | 2.13 | 1.50-3.01 | <.001 |
| Donor/recipient CMV serostatus | ||||
| +/+ | 287 | Reference | ||
| +/− | 55 | 0.40 | 0.18-0.86 | .02 |
| −/+ | 143 | 0.78 | 0.51-1.19 | .25 |
| −/− | 121 | 0.56 | 0.34-0.92 | .02 |
| Relapse | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| 7/8 HLA-MUD HCT | 227 | 0.81 | 0.57-1.13 | .22 |
| Remission status | ||||
| CR1 | 414 | Reference | ||
| CR2+ | 194 | 2.39 | 1.76-3.25 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 124 | Reference | ||
| White non-Hispanic | 277 | 0.94 | 0.64-1.39 | .76 |
| Black | 75 | 1.24 | 0.76-2.02 | .38 |
| Asian | 32 | 0.36 | 0.14-0.93 | .03 |
| Other/not specified | 100 | 0.58 | 0.34-0.99 | .05 |
| Conditioning regimen | ||||
| MAC-TBI | 295 | Reference | ||
| MAC-chemotherapy | 111 | 1.60 | 1.05-2.44 | .03 |
| RIC/NMA | 201 | 2.09 | 1.49-2.95 | <.001 |
| aGVHD, grade 2-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| 7/8 HLA-MUD HCT | 216 | 1.33 | 1.02-1.73 | .04 |
| Conditioning regimen | ||||
| MAC-TBI | 288 | Reference | ||
| MAC-chemotherapy | 107 | 0.68 | 0.47-0.98 | .04 |
| RIC/NMA | 196 | 0.68 | 0.51-0.92 | .01 |
| aGVHD, grade 3-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| 7/8 HLA-MUD HCT | 216 | 1.86 | 1.23-2.80 | .003 |
| cGVHD | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| 7/8 HLA-MUD HCT | 230 | 1.72 | 1.34-2.20 | <.001 |